BRPI0908271A2 - método para alcançar níveis plasmáticos desejados de fator de crescimento glial - Google Patents

método para alcançar níveis plasmáticos desejados de fator de crescimento glial

Info

Publication number
BRPI0908271A2
BRPI0908271A2 BRPI0908271A BRPI0908271A BRPI0908271A2 BR PI0908271 A2 BRPI0908271 A2 BR PI0908271A2 BR PI0908271 A BRPI0908271 A BR PI0908271A BR PI0908271 A BRPI0908271 A BR PI0908271A BR PI0908271 A2 BRPI0908271 A2 BR PI0908271A2
Authority
BR
Brazil
Prior art keywords
growth factor
plasma levels
achieve desired
desired plasma
glial growth
Prior art date
Application number
BRPI0908271A
Other languages
English (en)
Inventor
O Caggiano Anthony
Kim Haesun
Original Assignee
Acorda Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Acorda Therapeutics Inc filed Critical Acorda Therapeutics Inc
Publication of BRPI0908271A2 publication Critical patent/BRPI0908271A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1883—Neuregulins, e.g.. p185erbB2 ligands, glial growth factor, heregulin, ARIA, neu differentiation factor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/51—Lyases (4)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6872—Intracellular protein regulatory factors and their receptors, e.g. including ion channels
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/475—Assays involving growth factors
    • G01N2333/4756—Neuregulins, i.e. p185erbB2 ligands, glial growth factor, heregulin, ARIA, neu differentiation factor
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G01N2800/285—Demyelinating diseases; Multipel sclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Cell Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Food Science & Technology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Analytical Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
BRPI0908271A 2008-02-29 2009-03-02 método para alcançar níveis plasmáticos desejados de fator de crescimento glial BRPI0908271A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US6758908P 2008-02-29 2008-02-29
PCT/US2009/001356 WO2009108390A2 (en) 2008-02-29 2009-03-02 Method for achieving desired glial growth factor 2 plasma levels

Publications (1)

Publication Number Publication Date
BRPI0908271A2 true BRPI0908271A2 (pt) 2017-06-13

Family

ID=41016663

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0908271A BRPI0908271A2 (pt) 2008-02-29 2009-03-02 método para alcançar níveis plasmáticos desejados de fator de crescimento glial

Country Status (11)

Country Link
US (5) US8410050B2 (pt)
EP (3) EP2262527B1 (pt)
JP (2) JP5697455B2 (pt)
CN (2) CN102026651B (pt)
AU (1) AU2009217606B2 (pt)
BR (1) BRPI0908271A2 (pt)
CA (1) CA2717193C (pt)
ES (2) ES2613177T3 (pt)
PL (1) PL2262527T4 (pt)
RU (3) RU2530650C2 (pt)
WO (1) WO2009108390A2 (pt)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8410050B2 (en) * 2008-02-29 2013-04-02 Acorda Therapeutics, Inc. Method for achieving desired glial growth factor 2 plasma levels
EP3632459A1 (en) 2008-07-17 2020-04-08 Acorda Therapeutics, Inc. Therapeutic dosing of a neuregulin or a subsequence thereof for treatment or prophylaxis of heart failure
CN107041949A (zh) 2008-08-15 2017-08-15 阿索尔达治疗公司 在cns神经性损伤后非‑急性期间处理的组合物及方法
BR112012008821A2 (pt) 2009-10-14 2020-09-15 Acorda Therapeutics, Inc. uso de neuregulina para tratar lesões nervosas periféricas.
JP2013529911A (ja) * 2010-05-28 2013-07-25 マインド−エヌアールジー ソシエテ アノニム ニューレグリンアイソフォーム、ニューレグリンポリペプチドおよびその使用法
JP2013535507A (ja) * 2010-08-13 2013-09-12 ジョージタウン ユニバーシティ Ｇｇｆ２および使用方法
JP6420233B2 (ja) * 2012-03-30 2018-11-07 アコーダ セラピューティクス，インコーポレーテッド 末梢神経損傷を処置するためのニューレグリンの使用
US11207354B2 (en) * 2016-09-23 2021-12-28 Osaka University Schwann cell differentiation promoting agent and a peripheral nerve regeneration promoting agent
CN108653274B (zh) * 2017-04-01 2022-09-16 鲁南制药集团股份有限公司 牛蒡子苷元在制备治疗骨髓损伤药物中的用途

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7319019B1 (en) 1991-04-10 2008-01-15 Acorda Therapeutics, Inc. Glial mitogenic factors lacking an N-terminal signal sequence
US5716930A (en) 1991-04-10 1998-02-10 Ludwig Institute For Cancer Research Glial growth factors
US5530109A (en) 1991-04-10 1996-06-25 Ludwig Institute For Cancer Research DNA encoding glial mitogenic factors
US7135456B1 (en) 1991-04-10 2006-11-14 Acorda Therapeutics, Inc. Glial mitogenic factors, their preparation and use
US7037888B1 (en) 1992-04-03 2006-05-02 Acorda Therapeutics, Inc. Methods for treating muscle diseases and disorders
GB9217316D0 (en) * 1992-08-14 1992-09-30 Ludwig Inst Cancer Res Schwann cell mitogenic factor,its preparation and use
US5912326A (en) 1995-09-08 1999-06-15 President And Fellows Of Harvard College Cerebellum-derived growth factors
AU3003701A (en) 1999-11-19 2001-05-30 Axxima Pharmaceuticals Ag Inhibitors of helicobacter pylori induced gastrointestinal diseases
US20030232761A1 (en) 2002-03-28 2003-12-18 Hinke Simon A. Novel analogues of glucose-dependent insulinotropic polypeptide
EP1646353A4 (en) * 2003-05-16 2008-06-04 Acorda Therapeutics Inc FUSION PROTEINS FOR THE TREATMENT OF THE CENTRAL NERVOUS SYSTEM
US20080213817A1 (en) * 2004-02-19 2008-09-04 Michael Karin Enhancement of Th2-Dependent and Inflammatory Response
CA2596799A1 (en) 2005-02-02 2006-08-10 Nexuspharma Inc. Amine derivative containing compositions and methods for the treatment of viral infections related to the etiology of cancer
CA2658326C (en) 2005-09-02 2013-04-23 Morehouse School Of Medicine Neuregulins for prevention and treatment of damage from acute assault on vascular and neuronal tissue
US20080003013A1 (en) * 2006-06-30 2008-01-03 Static Control Components, Inc. Cartridge split rail clip
US8410050B2 (en) 2008-02-29 2013-04-02 Acorda Therapeutics, Inc. Method for achieving desired glial growth factor 2 plasma levels
RU2515236C1 (ru) 2010-04-01 2014-05-10 Дзе Проктер Энд Гэмбл Компани Мягчитель ткани
JP2013535507A (ja) 2010-08-13 2013-09-12 ジョージタウン ユニバーシティ Ｇｇｆ２および使用方法

Also Published As

Publication number Publication date
JP5964920B2 (ja) 2016-08-03
EP3750551A1 (en) 2020-12-16
JP2011513310A (ja) 2011-04-28
CN104645315A (zh) 2015-05-27
US20130345131A1 (en) 2013-12-26
EP3120863B1 (en) 2020-05-06
RU2530650C2 (ru) 2014-10-10
US9744215B2 (en) 2017-08-29
EP3120863A1 (en) 2017-01-25
CN102026651A (zh) 2011-04-20
US20210060128A1 (en) 2021-03-04
RU2014131265A (ru) 2016-02-20
JP2015042656A (ja) 2015-03-05
US10675331B2 (en) 2020-06-09
WO2009108390A2 (en) 2009-09-03
US8410050B2 (en) 2013-04-02
PL2262527T3 (pl) 2017-07-31
RU2019110452A (ru) 2020-10-09
ES2811127T3 (es) 2021-03-10
JP5697455B2 (ja) 2015-04-08
AU2009217606B2 (en) 2015-03-05
US20160367634A1 (en) 2016-12-22
US20100029559A1 (en) 2010-02-04
PL2262527T4 (pl) 2017-07-31
US9272015B2 (en) 2016-03-01
CN102026651B (zh) 2015-06-03
AU2009217606A1 (en) 2009-09-03
CA2717193A1 (en) 2009-09-03
EP2262527B1 (en) 2016-08-03
EP2262527A2 (en) 2010-12-22
WO2009108390A3 (en) 2010-11-18
RU2010139906A (ru) 2012-04-10
ES2613177T3 (es) 2017-05-23
US20180055909A1 (en) 2018-03-01
RU2687097C2 (ru) 2019-05-07
CA2717193C (en) 2022-08-16

Similar Documents

Publication Publication Date Title
BRPI0908271A2 (pt) método para alcançar níveis plasmáticos desejados de fator de crescimento glial
BR112012004094A2 (pt) composições de fator vii de coagulação e métodos para fazer e usar as mesmas
WO2011038389A9 (en) Methods of reducing plant stress
IL207752A0 (en) Methods of treating inflammation
BRPI0813124A2 (pt) Método de aperfeiçoamento do crescimento de uma planta
WO2010042548A9 (en) Methods of treating inflammation
DK2799067T3 (da) Behandling af hjerneinflammation ved anvendelse af L-Ornithin-phenylacetat
DK2569438T3 (da) Fremgangsmåde til fremstilling af biogas
EP2343441A4 (en) METHOD FOR MANUFACTURING A VARIABLE INCIDENCE BLADE
BRPI0823276A2 (pt) Método para aplicar uma composição de indicador a uma área desejada de um substrato
BR112013013765A2 (pt) método para inibição de crescimento de biofilme microbiano
SMT201400061B (it) Procedimento di preparazione di esteri attivati
EP2278993A4 (en) METHOD FOR PROMOTING HEALING
BR112014002804A2 (pt) revestimento e método de preparação do mesmo
CU24148B1 (es) Intermedios de agomelatina y método de preparación de éstos
SI2234472T1 (sl) Postopek za gojenje rastlin
FI20105638A0 (fi) Kivipinnoitteen valmistus
EP2249863A4 (en) METHOD OF ENHANCING WOUND HEALING
FI20105250A0 (fi) Menetelmä tornimaisten rakenteiden perustusten yhteydessä ja tornimaisten rakenteiden perustus
UY33136A (es) Tropinonabencilaminas como inhibidores de la beta-triptasa
HRP20150022T1 (hr) Upotreba azaperona za poboljšanje rasta
FI20105265A0 (fi) Jäähdytin ja valmistusmenetelmä
FI20105500A0 (fi) Menetelmä kipsin valmistamiseksi
GB0821365D0 (en) Method of manufacture
AU2009901325A0 (en) Method of Tissue Repair

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]
B12B Appeal against refusal [chapter 12.2 patent gazette]
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 15A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2764 DE 26-12-2023 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.